Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-08
2006-08-08
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S209000, C548S146000
Reexamination Certificate
active
07087623
ABSTRACT:
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various mammalian cellular receptors, including G-protein coupled receptors. A third aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors or transporters. Another aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, Tourette's syndrome, psychiatric disorders, stroke, senile dementia, peptic ulcers, pulmonary obstruction disorders, and asthma.
REFERENCES:
patent: 5017579 (1991-05-01), Gubin et al.
patent: 5081119 (1992-01-01), Boigegrain et al.
patent: 5232921 (1993-08-01), Biziere et al.
patent: 5462939 (1995-10-01), Dolle et al.
patent: 5464847 (1995-11-01), Courtemanche et al.
patent: 5674890 (1997-10-01), Christophe et al.
patent: 5780468 (1998-07-01), Bernat et al.
patent: 6057340 (2000-05-01), Kelly et al.
patent: 6107313 (2000-08-01), Williams et al.
patent: 0 283 390 (1988-09-01), None
patent: 0 636 624 (1995-02-01), None
patent: 0 702015 (1996-03-01), None
patent: 0659747 (1998-04-01), None
patent: WO 91/09857 (1991-07-01), None
patent: WO 92/03134 (1992-03-01), None
patent: WO 95/07694 (1995-03-01), None
patent: WO 98/25904 (1998-06-01), None
patent: WO 98/41528 (1998-09-01), None
patent: WO 99/11637 (1999-03-01), None
patent: WO 99/32464 (1999-07-01), None
patent: WO 99/62890 (1999-12-01), None
Williams, et al.; “A Solution-Phase Combinatorial Synthesis of Selective Dopamine D4 Ligands,” Combinatorial Chemistry and High Throughput Screening, 2000, vol. 3, No. 1, pp. 43-50.
Cuny Gregory D.
Hauske James R.
Heffernan Michele L. R.
Holland Joanne M.
Persons Paul E.
Foley & Hoag LLP
Gordon Dana M.
Sepracor Inc.
Shiao Robert
Solola Taofiq
LandOfFree
Thiazole and other heterocyclic ligands for mammalian... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiazole and other heterocyclic ligands for mammalian..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazole and other heterocyclic ligands for mammalian... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3634978